GSK Invites Private Equity Bids for Older Drugs

UK pharmaceutical producer GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs, news agencies report, citing people familiar with the matter.

The move is said to be part of a reshaping of the drugmaker's portfolio, which also involves a $20 billion asset swap with Novartis that will see the Swiss company acquiring GSK's oncology activities while GSK takes Novartis' vaccines business.

GSK chief Andrew Witty said last month that Britain's biggest pharmaceuticals company could dispose of individual medicines or a broader portfolio of older established products.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.